UnitedHealth Group Sells Brazil Unit for $1.7B
Ticker: UNH · Form: 8-K · Filed: Mar 21, 2024 · CIK: 731766
| Field | Detail |
|---|---|
| Company | Unitedhealth Group Inc (UNH) |
| Form Type | 8-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $500,000,000, $400,000,000, $1,000,000,000, $1,250,000,000, $1,750,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: divestiture, international-operations, strategic-shift
Related Tickers: UNH
TL;DR
UNH selling Amil in Brazil for $1.7B to focus on US ops.
AI Summary
UnitedHealth Group Inc. announced on March 19, 2024, that it has entered into a definitive agreement to sell its Brazil-based health services business, Amil, to a consortium led by the private equity firm North Haven for approximately $1.7 billion. This divestiture is part of UnitedHealth Group's strategy to focus on its core businesses in the United States.
Why It Matters
This sale allows UnitedHealth Group to streamline its operations and concentrate on its domestic market, potentially improving financial performance and strategic focus.
Risk Assessment
Risk Level: low — The sale of a non-core international asset is a strategic decision with limited immediate risk to the core business.
Key Numbers
- $1.7B — Sale Price (Divestiture of Amil business in Brazil)
Key Players & Entities
- UnitedHealth Group Inc. (company) — Seller
- Amil (company) — Business being sold
- North Haven (company) — Buyer
- $1.7 billion (dollar_amount) — Sale price
- March 19, 2024 (date) — Announcement date
FAQ
What is the name of the business UnitedHealth Group is selling in Brazil?
UnitedHealth Group is selling its Brazil-based health services business named Amil.
Who is acquiring Amil from UnitedHealth Group?
Amil is being acquired by a consortium led by the private equity firm North Haven.
What is the approximate sale price for Amil?
The approximate sale price for Amil is $1.7 billion.
On what date was this definitive agreement announced?
The definitive agreement was announced on March 19, 2024.
What is UnitedHealth Group's stated reason for selling Amil?
UnitedHealth Group is selling Amil as part of its strategy to focus on its core businesses in the United States.
Filing Stats: 1,056 words · 4 min read · ~4 pages · Grade level 8.9 · Accepted 2024-03-21 16:30:58
Key Financial Figures
- $500,000,000 — 27 in the aggregate principal amount of $500,000,000, (ii) 4.700% Notes due April 15, 2029 i
- $400,000,000 — 29 in the aggregate principal amount of $400,000,000, (iii) 4.900% Notes due April 15, 2031
- $1,000,000,000 — 31 in the aggregate principal amount of $1,000,000,000, (iv) 5.000% Notes due April 15, 2034 i
- $1,250,000,000 — 34 in the aggregate principal amount of $1,250,000,000, (v) 5.375% Notes due April 15, 2054 in
- $1,750,000,000 — 54 in the aggregate principal amount of $1,750,000,000 and (vi) 5.500% Notes due April 15, 206
- $1,100,000,000 — 64 in the aggregate principal amount of $1,100,000,000 (collectively, the "Notes"), pursuant t
Filing Documents
- d800516d8k.htm (8-K) — 32KB
- d800516dex11.htm (EX-1.1) — 100KB
- d800516dex12.htm (EX-1.2) — 106KB
- d800516dex41.htm (EX-4.1) — 130KB
- d800516dex42.htm (EX-4.2) — 133KB
- d800516dex43.htm (EX-4.3) — 132KB
- d800516dex44.htm (EX-4.4) — 131KB
- d800516dex45.htm (EX-4.5) — 131KB
- d800516dex46.htm (EX-4.6) — 131KB
- d800516dex51.htm (EX-5.1) — 13KB
- 0001193125-24-073887.txt ( ) — 1381KB
- unh-20240319.xsd (EX-101.SCH) — 3KB
- unh-20240319_lab.xml (EX-101.LAB) — 18KB
- unh-20240319_pre.xml (EX-101.PRE) — 11KB
- d800516d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 1.1 Underwriting Agreement, dated March 19, 2024, among the Company and BofA Securities, Inc., Barclays Capital Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as Representatives of the several Underwriters 1.2 Pricing Agreement, dated March 19, 2024, among the Company and BofA Securities, Inc., Barclays Capital Inc., J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as Representatives of the several Underwriters 4.1 Officers' Certificate and Company Order, dated March 21, 2024, relating to the 4.600% Notes due April 15, 2027, pursuant to Sections 201, 301 and 303 of the Indenture (including the form of 4.600% Notes due April 15, 2027) 4.2 Officers' Certificate and Company Order, dated March 21, 2024, relating to the 4.700% Notes due April 15, 2029, pursuant to Sections 201, 301 and 303 of the Indenture (including the form of 4.700% Notes due April 15, 2029) 4.3 Officers' Certificate and Company Order, dated March 21, 2024, relating to the 4.900% Notes due April 15, 2031, pursuant to Sections 201, 301 and 303 of the Indenture (including the form of 4.900% Notes due April 15, 2031) 4.4 Officers' Certificate and Company Order, dated March 21, 2024, relating to the 5.000% Notes due April 15, 2034, pursuant to Sections 201, 301 and 303 of the Indenture (including the form of 5.000% Notes due April 15, 2034) 4.5 Officers' Certificate and Company Order, dated March 21, 2024, relating to the 5.375% Notes due April 15, 2054, pursuant to Sections 201, 301 and 303 of the Indenture (including the form of 5.375% Notes due April 15, 2054) 4.6 Officers' Certificate and Company Order, dated March 21, 2024, relating to the 5.500% Notes due April 15, 2064, pursuant to Sections 201, 301 and 303 of the Indenture (including the form of 5.500% Notes due April 15, 2064) 5.1 Opinion of Hogan Lovells US LLP regarding the validity of the Notes 23.1 Consent
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 21, 2024 UNITEDHEALTH GROUP INCORPORATED By: /s/ Kuai H. Leong Name: Kuai H. Leong Title: Deputy Corporate Secretary